IIC
ALXN

Integrated Investment Consultants’s Alexion Pharmaceuticals ALXN Stock Holding History

Integrated Investment Consultants’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-626
Closed -$70K – 773
2018
Q1 		$70K Buy
+626
New +$74.8K 0.03% 387
2017
Q3 		$87K Buy
622
+25
+4% +$3.4K 0.04% 323
2017
Q2 		$73K Hold
597
– – 0.03% 347
2017
Q1 		$72K Sell
597
-128
-18% -$16.5K 0.03% 350
2016
Q4 		$89K Hold
725
– – 0.04% 297
2016
Q3 		$87K Hold
725
– – 0.04% 301
2016
Q2 		$85K Buy
725
+129
+22% +$18.3K 0.05% 307
2016
Q1 		$89K Buy
+596
New +$87.5K 0.05% 258

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Integrated Investment Consultants's ALXN Position: Q2 2018 in Review

Integrated Investment Consultants sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 626 shares — an estimated $70K sold.

Integrated Investment Consultants first reported a position in ALXN in Q1 2016 and held it in 8 quarters. The position peaked at $89K in Q4 2016. 601 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • Integrated Investment Consultants reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Integrated Investment Consultants sold 626 Alexion Pharmaceuticals shares in Q2 2018, an estimated $70K.
  • Integrated Investment Consultants first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 8 quarters.
  • Integrated Investment Consultants's Alexion Pharmaceuticals position peaked at $89K in Q4 2016.
  • 601 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Integrated Investment Consultants's 13F filing for Q2 2018, filed 1 Aug 2018.